Terminated PHASE2/PHASE3 INTERVENTIONAL 1-arm NCT04817761

SPARK-ALL: Calaspargase Pegol in Adults With ALL

SPARK-ALL: A Multi-center, Open-label, Single-arm Phase 2/3 Trial Evaluating the Safety and Pharmacokinetics of Calaspargase Pegol for Treatment of Adults Aged 22 To >65 Years With Newly-diagnosed Philadelphia-negative ALL.

Sponsor: ADIR, a Servier Group company

Conditions Acute Lymphoblastic Leukemia

Interventions Calaspargase pegol (S95015)

Updated 16 times since 2021 Last updated: Feb 16, 2026 Started: Jul 7, 2021 Primary completion: Mar 21, 2025 Completion: Mar 21, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision

Other terminated trials from ADIR, a Servier Group company

See all terminations from ADIR, a Servier Group company

Other Acute Lymphoblastic Leukemia trials with similar outcome

Browse all Acute Lymphoblastic Leukemia trials

A PHASE2/PHASE3 clinical study on Acute Lymphoblastic Leukemia, this trial is terminated or withdrawn. The trial is conducted by ADIR, a Servier Group company and has accumulated 16 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

16 versions recorded

Feb 2026 — Present [monthly]

Terminated PHASE2/PHASE3

Status: Active Not Recruiting → Terminated
Nov 2025 — Feb 2026 [monthly]

Active Not Recruiting PHASE2/PHASE3
Mar 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE2/PHASE3

Status: Recruiting → Active Not Recruiting
Jan 2025 — Mar 2025 [monthly]

Recruiting PHASE2/PHASE3
Oct 2024 — Jan 2025 [monthly]

Recruiting PHASE2/PHASE3

▶ Show 11 earlier versions

Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2/PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2/PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Mar 2024 — Jul 2024 [monthly]

Recruiting PHASE2_PHASE3
Nov 2023 — Mar 2024 [monthly]

Recruiting PHASE2_PHASE3
Jan 2023 — Nov 2023 [monthly]

Recruiting PHASE2_PHASE3
Sep 2022 — Jan 2023 [monthly]

Recruiting PHASE2_PHASE3
May 2022 — Sep 2022 [monthly]

Recruiting PHASE2_PHASE3
Apr 2022 — May 2022 [monthly]

Recruiting PHASE2_PHASE3
Nov 2021 — Apr 2022 [monthly]

Recruiting PHASE2_PHASE3

Status: Not Yet Recruiting → Recruiting
Apr 2021 — Nov 2021 [monthly]

Not Yet Recruiting PHASE2_PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

ADIR, a Servier Group company
Institut de Recherches Internationales Servier

Data source: Servier

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Baltimore, United States , Chicago, United States , Cleveland, United States , Duarte, United States , Durham, United States , Lake Success, United States , Los Angeles, United States , Memphis, United States , Miami, United States , Morgantown, United States and 9 more locations